Patrick Williams, MD
Ophthalmology · Arlington, TXNPI 1154306777
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,186 of the $16,689 with a category attached, or 79.0%. Regeneron Healthcare Solutions, Inc. accounts for 79.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $5,304 and has fallen 98.9% since, to $60 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $260.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$13K
- Carl Zeiss Meditec, Inc.$1K
- Novartis$656
- Genentech USA, Inc.$315
- Apellis Pharmaceuticals, Inc.$207
- Coherus Oncology, Inc.$154
- plus $600 from 8 others
Across 456 payments — averaging $14,434 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.3M
- Genentech, Inc.$1M
- Bayer$728K
- Kyowa Kirin, Inc.$335K
- Amgen$114K
- Janssen Research & Development, LLC$32K
- plus $17K from 1 others
What the payments were for
- Consulting fees$13,18679%
- Travel & lodging$5323%
- Food & beverage$1,4809%
- Education$320%
- Gifts$1,4599%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 17 | $13,299 |
| Carl Zeiss Meditec, Inc. | 1 | $1,459 |
| Novartis | 6 | $656 |
| Genentech USA, Inc. | 14 | $315 |
| Apellis Pharmaceuticals, Inc. | 4 | $207 |
| Coherus Oncology, Inc. | 5 | $154 |
| Ocular Therapeutix, Inc. | 4 | $150 |
| Neotract Inc. | 1 | $138 |
| Astellas Pharma US Inc | 4 | $116 |
| Alimera Sciences, Inc. | 3 | $69 |
| AbbVie(2 entities) | 2 | $50 |
| Sandoz | 1 | $28 |
| Genentech, Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,689 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 18 | $5,310 |
| Prednisolone Acetate | 120 | $3,747 |
| Difluprednate | 32 | $3,404 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 189 | $2,300 |
| Ketorolac Tromethamine | 81 | $1,586 |
| Brimonidine Tartrate | 11 | $933 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 57 | $657 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $483 |
| Latanoprost | 16 | $148 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Arlington
- Aaleya KoreishiArlington$144K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.